Cardiff Oncology, Inc. (CRDF) earnings
CRDF earnings moved a median of -0.10% by the close. Quarterly and annual CRDF reports and results, each read against the price at its own news timestamp. Back to the CRDF overview →
24 measured CRDF earnings events.
Where these CRDF earnings landedvs 24 measured CRDF earnings reactions
| Middle 50% of CRDF earnings reactions | -4.13% to +1.41% |
|---|---|
| Median reaction (to close) | -0.10% |
| Measured reactions | 24 |
Point-in-time · zero look-ahead
Half of the 24 CRDF earnings events with a measured close landed between -4.13% and +1.41%; 33% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update | Press release | +0.01% | -3.02% | |
| Form 10-Q Cardiff Oncology, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.85% | -0.21% | |
| Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Press release | -0.05% | -0.95% | |
| Form 10-Q Cardiff Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.05% | -0.95% | |
| Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Press release | +1.51% | +1.21% | |
| Form 10-Q Cardiff Oncology, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.51% | +1.21% | |
| Form 10-K Cardiff Oncology, Inc. For: Dec 31 | SEC filing · Form 10-K | +4.54% | +8.52% | |
| Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update | Press release | +1.60% | +0.00% | |
| Form 10-Q Cardiff Oncology, Inc. For: Sep 30 | SEC filing · Form 10-Q | +1.60% | +0.00% | |
| Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update | Press release | -8.74% | -7.43% | |
| Form 10-Q Cardiff Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | -8.74% | -7.43% | |
| Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update | Press release | +1.95% | +0.00% | |
| Form 10-Q Cardiff Oncology, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.95% | +0.00% | |
| Form 10-K Cardiff Oncology, Inc. For: Dec 31 | SEC filing · Form 10-K | +5.71% | +5.21% | |
| Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update | Press release | -2.47% | -2.26% | |
| Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update | Press release | -12.95% | -25.42% | |
| Form 10-Q Cardiff Oncology, Inc. For: Sep 30 | SEC filing · Form 10-Q | -12.95% | -25.42% | |
| Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update | Press release | +3.24% | +10.19% | |
| Form 10-Q Cardiff Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | +3.24% | +10.19% | |
| Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update | Press release | -1.78% | -0.44% | |
| Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update | Press release | +8.54% | -11.56% | |
| Form 10-Q Cardiff Oncology, Inc. For: Mar 31 | SEC filing · Form 10-Q | +8.54% | -11.56% | |
| Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update | Press release | +1.75% | +2.00% | |
| Form 10-K Cardiff Oncology, Inc. For: Dec 31 | SEC filing · Form 10-K | +4.00% | +45.50% |
Keep exploring
More CRDF: analyst actions → · SEC filings → · CRDF overview →